Brief: Pliant Therapeutics Receives FDA Fast Track Designation For PLN-101095 In Combination With Pembrolizumab For The Treatment Of Ici-Refractory Solid Tumors
18/08/2026 13:31
BRIEF-Pliant Therapeutics Receives FDA Fast Track Designation For PLN-101095 In Combination With Pembrolizumab For The Treatment Of Ici-Refractory Solid Tumors Pliant Therapeutics, Inc. PLRX.O:
PLIANT THERAPEUTICS RECEIVES FDA FAST TRACK DESIGNATION FOR PLN-101095 IN COMBINATION WITH PEMBROLIZUMAB FOR THE TREATMENT OF ICI-REFRACTORY SOLID TUMORS
PLIANT THERAPEUTICS, - PLN-101095 DATA FROM PHASE 1A/1B FORTIFY TRIAL EXPECTED IN 2027
Source text: ID:nGNX4JHQr5
Further company coverage: PLRX.O
Recent news on Pliant Therapeutics
See all newsBrief: Pliant Therapeutics Announces Presentations At The 2026 Annual Meeting
Brief: Pliant Therapeutics Appoints David Raben, M.D., As Chief Medical Officer
RCS - Redx Pharma Limited - Redx Announces Final Audited Results
RCS - Redx Pharma Limited - Close of Series A; Strengthened Board Composition
U.S. STOCKS ON THE MOVE-Gold miners, Weave Communications, Amylyx Pharmaceuticals